ALK+ Blog/News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
Managing Lorlatinib Together: What Patients and Experts Want You to Know
“Patients can—and should—have a voice in their care. This guide is about giving them the tools to do just that.” — Nancee Pronsati, ALK Positive Inc.
-
Instructions and Call for Patient Participation in The University of Michigan Judith Tam ALK Lung Cancer Research Initiative
Help Advance Personalized ALK+ Research with the University of Michigan The Judith Tam ALK Lung Cancer Research Initiative at the University of Michigan is leading a groundbreaking effort to better understand and treat ALK-positive non-small cell lung cancer (NSCLC). By collecting patient samples—blood, tumor tissue, and malignant fluid—over time, researchers are building a deep, individualized…
-
Introducing Oncogene Cancer Research
An interview with Co-founder & Chair, Yvonne Diaz (also a Board Member of ALK Positive Inc) This month, we speak with Yvonne Diaz, a Board Member of ALK Positive Inc and the co-founder of Oncogene Cancer Research, a UK-based patient organization dedicated to empowering patients, championing advocacy, and accelerating clinical research.
-
-
Clinical Trial Spotlight: Tumor-Infiltrating Lymphocyte Therapy for ALK-Positive NSCLC at Moffitt Cancer Center
For ALK-positive patients who have progressed after targeted therapy, a new clinical trial at Moffitt Cancer Center offers renewed hope. This Phase 1 study explores an enhanced form of Tumor-Infiltrating Lymphocyte (TIL) therapy—empowering a patient’s own immune cells with a genetic boost to better recognize and fight cancer. With its focus on ALK, EGFR, ROS1,…
-
Patient Spotlight: Rick Meyer
We interviewed long term survivor Rick Meyer on his experience with multiple ALK TKIs, his participation in the Nuvalent clinical trial for almost two years and counting, and his overall attitude to life as a thriving ALK patient.
-
Stronger Every Day: How Movement and Community Keep Me Going
When Michele walked into PVolve, she was looking for a way to reconnect with her body after a life-changing cancer diagnosis. What she found was so much more—a community that believed in her, showed up for her, and helped her raise nearly $5,000 for ALK-positive lung cancer research. This is her story of movement, resilience,…
-
Trivia for a Cure: How Nikki Turned a Night of Fun into a Force for Research
Nikki never imagined hosting a fundraiser in her name—let alone speaking publicly about her diagnosis. But when her community rallied around her, Trivia Night for a Cause became more than an event. It became a moment of courage, connection, and clarity. Learn how Nikki raised over $6,000 for ALK research and helped start an annual…
-
$8 to the Greats: Because Great Things Start Small
Suzanne believes in the power of small gifts and strong communities. That’s why she launched 8 to the Greats—a way for anyone to give $8 a month to fund lifesaving ALK research. Because we’re truly stronger together.
-
A Journey of Purpose: How One Traveler Turned Airfare into Hope
After two decades in the travel industry, Keng was diagnosed with ALK-positive lung cancer—and everything changed. Blending his professional expertise with a new sense of purpose, he created HealthcareFares.com, a platform that lets travelers save on flights and fund cancer research at no extra cost.
-
Patient Spotlight: Celeste Olinger Denver, Colorado, USA
We interviewed long-term ALK survivor, Celeste Olinger, about her somewhat unusual cancer journey, her life, and her new normal since her diagnosis that still keeps her grounded and allows her to thrive.
-
Clinical Trials for ALK-positive Cancers – Are They for Me?
Should I enroll in a clinical trial for ALK-positive cancer? The decision to enroll in a clinical trial requires a real understanding of what is being studied and how you will participate in the study. It is important to remember that clinical trials have been instrumental in developing all treatments for ALK-positive cancers. Many of…